Cutaneous and systemic treatment-related adverse events as prognostic markers in immunotherapy and targeted therapy, with a focus on melanoma.
Crespi Orsola O, Santaniello Umberto U, Rosset François F, Pala Valentina V et al.
Immune checkpoint inhibitors (ICIs) and targeted therapies have transformed the management of advanced malignancies but are associated with characteristic adverse events (AEs), many of which are skin-predominant. Increasing evidence indicates that selected treatment-related AEs, particularly immune-related adverse events (irAEs) and on-target toxicities, may serve as dynamic biomarkers of antitumor activity. This review summarizes current data on the incidence, spectrum, and prognostic significance of irAEs and targeted-therapy AEs, with a specific emphasis on cutaneous events relevant to dermatologists. We highlight the robust association between cutaneous irAEs (cirAEs) - including vitiligo, regression of melanocytic nevi and halo phenomena in melanoma - and improved clinical outcomes. We also examine prognostic data for other cutaneous patterns (lichenoid, psoriasiform, bullous), endocrine and other organ-specific irAEs, and on-target dermatologic toxicities under epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR), and BRAF/MEK inhibition. Finally, we discuss mechanistic hypotheses and practical implications for dermatology practice, stressing the need to balance recognition of toxicity as a favorable biomarker with timely management to avoid treatment interruption.